脂质纳米粒子介导的mRNA输送到老鼠和人类视网膜和其他眼睛组织中
Cheri Z Chambers1, Gillian L Soo1, Abbi L Engel1
1Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA, USA.
Translational vision science & technology
|July 9, 2024
概括
脂质纳米颗粒有效地在小鼠和人眼组织 (包括视网膜) 中传递mRNA用于基因表达. 这种非病毒性方法对未来的眼部基因疗法显示出有前途,没有显著的炎症.
科学领域:
- 眼科医生 眼科 眼科
- 基因治疗 基因治疗
- 纳米医学是一种纳米医学.
背景情况:
- 脂质纳米颗粒 (LNP) 提供了一种有前途的非病毒方法,用于将mRNA输送到眼部组织.
- 眼睛中的基因疗法旨在在特定细胞类型中表达治疗性蛋白质.
- 腺相关病毒 (AAV) 载体是常用的,但非病毒方法正在作为替代品被探索.
研究的目的:
- 评估包装在LNP中的mRNA在驱动小鼠和人类眼组织中的基因表达中的有效性.
- 评估LNP输送后视网膜细胞中基因表达的特异性.
- 调查LNP作为眼部应用的非病毒基因传递系统的潜力.
主要方法:
- 携带mRNA的LNP通过静脉内注射被引入小鼠的眼睛.
- 人类视网膜色素表皮质 (RPE) 和视网膜扩增剂被用于评估人类组织中的基因表达.
- 组织学,免疫光学和成像学被用来分析表达特异性.
主要成果:
- 在小鼠中,编码GFP和状神经变因子 (CNTF) 的mRNA被Müller glia和RPE特异地表达.
- 在注射后6小时的小鼠中没有观察到急性炎症变化.
- 人类RPE表达了高水平的GFP,而人类视网膜扩展体显示了Müller状细胞和巨细胞中的GFP表达.
结论:
- 视网膜细胞亚群的可靠传染被证明是体内 (老鼠) 和体外 (人) 眼组织.
- 对于小鼠的RPE转染,静脉内注射足够.
- 这项研究代表了使用LNP在人眼组织中进行mRNA输送的首次演示.
相关概念视频
Regulated mRNA Transport
In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing specific...
Nucleic Acid Structure
The pentose sugar in DNA is deoxyribose, while in RNA the pentose sugar is ribose. The difference between the sugars is the presence of the hydroxyl group on the ribose's second carbon and a hydrogen on the deoxyribose's second carbon. The phosphate residue attaches to the hydroxyl group of the 5′ carbon of one sugar and the hydroxyl group of the 3′ carbon of the sugar of the next nucleotide, which forms a 5′ to 3′ phosphodiester linkage.
DNA Structure
DNA has a double-helix structure. The...
DNA Structure
DNA has a double-helix structure. The...


